These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26023085)

  • 1. Inhibition of JNK Sensitizes Hypoxic Colon Cancer Cells to DNA-Damaging Agents.
    Vasilevskaya IA; Selvakumaran M; Hierro LC; Goldstein SR; Winkler JD; O'Dwyer PJ
    Clin Cancer Res; 2015 Sep; 21(18):4143-52. PubMed ID: 26023085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy.
    Selvakumaran M; Amaravadi RK; Vasilevskaya IA; O'Dwyer PJ
    Clin Cancer Res; 2013 Jun; 19(11):2995-3007. PubMed ID: 23461901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of signaling through SEK1 and MKK7 yields differential responses in hypoxic colon cancer cells treated with oxaliplatin.
    Vasilevskaya IA; Selvakumaran M; O'Dwyer PJ
    Mol Pharmacol; 2008 Jul; 74(1):246-54. PubMed ID: 18436711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JNK1 Inhibition Attenuates Hypoxia-Induced Autophagy and Sensitizes to Chemotherapy.
    Vasilevskaya IA; Selvakumaran M; Roberts D; O'Dwyer PJ
    Mol Cancer Res; 2016 Aug; 14(8):753-63. PubMed ID: 27216154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis.
    Selvakumaran M; Yao KS; Feldman MD; O'Dwyer PJ
    Biochem Pharmacol; 2008 Feb; 75(3):627-38. PubMed ID: 18178171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells.
    Raymond E; Louvet C; Tournigand C; Coudray AM; Faivre S; De Gramont A; Gespach C
    Int J Oncol; 2002 Aug; 21(2):361-7. PubMed ID: 12118332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
    El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
    Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
    Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
    Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
    Ikehata M; Ogawa M; Yamada Y; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2014; 37(1):67-73. PubMed ID: 24172061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
    Na YS; Kim SM; Jung KA; Yang SJ; Hong YS; Ryu MH; Ro S; Cho DH; Kim JC; Jin DH; Lee JS; Kim TW
    Oncol Rep; 2010 Dec; 24(6):1509-14. PubMed ID: 21042746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy.
    Lipner MB; Peng XL; Jin C; Xu Y; Gao Y; East MP; Rashid NU; Moffitt RA; Herrera Loeza SG; Morrison AB; Golitz BT; Vaziri C; Graves LM; Johnson GL; Yeh JJ
    JCI Insight; 2020 Apr; 5(8):. PubMed ID: 32213714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
    Attoub S; Arafat K; Khalaf T; Sulaiman S; Iratni R
    Nutrients; 2018 May; 10(5):. PubMed ID: 29724012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling.
    Rakitina TV; Vasilevskaya IA; O'Dwyer PJ
    Cancer Res; 2003 Dec; 63(24):8600-5. PubMed ID: 14695170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib as a potential adjuvant chemotherapy agent in disseminated small colon cancer: Drug selection outcome of a novel screening system using nanoimprinting 3-dimensional culture with HCT116-RFP cells.
    Yoshii Y; Furukawa T; Aoyama H; Adachi N; Zhang MR; Wakizaka H; Fujibayashi Y; Saga T
    Int J Oncol; 2016 Apr; 48(4):1477-84. PubMed ID: 26820693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
    Raymond E; Buquet-Fagot C; Djelloul S; Mester J; Cvitkovic E; Allain P; Louvet C; Gespach C
    Anticancer Drugs; 1997 Oct; 8(9):876-85. PubMed ID: 9402315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
    Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
    Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.